Synthesis of vinylcyclobutyl intermediates

Abstract

To provide intermediates useful in preparing Mcl-1 inhibitors.SOLUTION: The invention provides compounds having the structure of formula (I), where R1 is one of the middle formulas in the figure or a protected aldehyde, and R2 is OH or OPG2, where OPG2 is a secondary alcohol protecting group, provided that if R2 is OH then R1 is the structure of the lowest formula in the figure.SELECTED DRAWING: None

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 020,877, filed May 6, 2020, which is incorporated by reference in its entirety for all purposes as if fully set forth herein.

[0002] The present disclosure relates to (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (compound A1; AMG176), its salt or solvate, and (1S,3'R,6'R,7'R,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-7'-((9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylmethyl)-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0] 3,6 .0 19,24 The present invention relates to intermediates used in the synthesis of pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (compound A2; AMG397), salts or solvates thereof, and methods for synthesizing the intermediates. These compounds are inhibitors of myeloid cell leukemia 1 protein (Mcl-1). [Background technology]

[0003] The compound (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0] 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (compound A1): [ka] are useful as inhibitors of myeloid cell leukemia 1 (Mcl-1).

[0004] The compound (1S,3'R,6'R,7'R,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-7'-((9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylmethyl)-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0] 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (compound A2): [ka] are useful as inhibitors of myeloid cell leukemia 1 (Mcl-1).

[0005] One common characteristic of human cancers is overexpression of Mcl-1, which prevents cancer cells from undergoing programmed cell death (apoptosis) and allows them to survive despite extensive genetic damage.

[0006] Mcl-1 is a member of the Bcl-2 family of proteins. The Bcl-2 family includes pro-apoptotic members (such as BAX and BAK), which upon activation form homo-oligomers in the outer mitochondrial membrane, leading to pore formation and mitochondrial content evacuation, a step that triggers apoptosis. Anti-apoptotic members of the Bcl-2 family (such as Bcl-2, Bcl-XL, and Mcl-1) block the activity of BAX and BAK. Other proteins (such as BID, BIM, BIK, and BAD) exhibit additional regulatory functions. Studies have shown that Mcl-1 inhibitors may be useful for the treatment of cancer. Mcl-1 is overexpressed in many cancers.

[0007] U.S. Patent No. 9,562,061, the entirety of which is incorporated herein by reference, discloses compound A1 as an Mcl-1 inhibitor and provides a method for its preparation. However, improved synthetic methods that result in higher yields and purity of compound A1 are desirable, particularly for commercial production of compound A1.

[0008] U.S. Patent No. 10,300,075, the entirety of which is incorporated herein by reference, discloses compound A2 as an Mcl-1 inhibitor and provides a method for its preparation. However, improved synthetic methods that result in higher yields and purity of compound A2 are desirable, particularly for commercial production of compound A2. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] U.S. Patent No. 9,562,061 [Patent Document 2] U.S. Patent No. 10,300,075 Summary of the Invention [Means for solving the problem]

[0010] As used herein, compound F [ka] (In the formula, OPG 2 is a secondary alcohol protecting group, and R 1 is a protected aldehyde) or a salt thereof, comprising: (a) protecting a secondary alcohol of compound B or a salt thereof by reacting compound B or a salt thereof with an alcohol protecting group reagent to produce compound C: [ka] or a salt thereof; (b) Removal of the acetyl group of compound C to give compound D: [ka] or a salt thereof; and (c) oxidizing the primary alcohol of compound D or a salt thereof to obtain compound E: [ka] or a salt thereof; and (d) protecting the aldehyde of compound E or a salt thereof to form a protected aldehyde of compound F or a salt thereof; A method is provided that includes:

[0011] In various embodiments, the OPG 2 includes acyl protecting groups, ether protecting groups, acetal or ketal protecting groups, sulfonyl protecting groups, and silyl ether protecting groups. In some cases, the acyl protecting group is selected from the group consisting of acetyl, pivaloyl, benzoyl, 4-bromobenzoyl, 4-chlorobenzoyl, 4-iodobenzoyl, 4-fluorobenzoyl, 4-nitrobenzoyl, 4-phenylbenzoyl, 1-naphthoyl, 2-naphthoyl, 4-methoxybenzoyl, and isobutyryl. In some cases, the acyl protecting group is 4-bromobenzoyl.

[0012] In various embodiments, the alcohol protecting group reagent in step (a) is an acyl chloride or an acyl anhydride.

[0013] In various embodiments, compound B and the alcohol protecting group reagent are present in a molar ratio of 1:1 to 1:2. In some cases, the molar ratio of compound B to alcohol protecting group reagent is 1:1.3.

[0014] In various embodiments, the OPG 2 teeth, [ka] (methoxy), [ka] (tert-butyl ether), [ka] (methoxymethyl acetal, MOM), [ka] (2-methoxyethoxymethyl ether, MEM), [ka] (ethoxyethyl acetal, EE), [ka] (methoxypropyl acetal, MOP), [ka] (tetrahydropyranyl acetal, THP), [ka] (benzyloxymethyl acetal, BOM), [ka] (benzyl ether, Bn), [ka] (4-methoxybenzyl ether, PMB), [ka] (2-naphthyl methyl ether, Nap), [ka] (acetyl, Ac), [ka] Pivaloyl (Piv), [ka] (benzoyl, Bz), [ka] (4-bromobenzoyl, Br-Bz), [ka] (4-fluorobenzoyl), [ka] (4-chlorobenzoyl), [ka] (4-iodobenzoyl), [ka] (4-nitrobenzoyl), [ka] (4-phenylbenzoyl), [ka] (1-naphthoyl ester), [ka] (2-naphthoyl ester), [ka] (4-methoxybenzoyl), [ka] (isobutyryl), OSO2Me (mesyl), [ka] (4-toluenesulfonyl, tosyl), [ka] (4-nitrobenzenesulfonyl, nosyl) and OSO2CF3 (triflyl). In various embodiments, the silyl ether protecting group is selected from the group consisting of OSiEt3 (triethylsilyl ether, TES), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), and OSiPh2 t Bu(tert-butyldiphenylsilyl ether TBDPS).

[0015] In various embodiments, step (a) comprises combining compound B or a salt thereof, an alcohol protecting group reagent, and a nucleophilic catalyst. In various embodiments, the nucleophilic catalyst comprises pyridine, 4-dimethylaminopyridine, or a combination thereof. In various embodiments, compound B and the nucleophilic catalyst are present in a molar ratio of 1:1 to 1:5. In some cases, the molar ratio of compound B to the nucleophilic catalyst is 1:2.

[0016] In various embodiments, step (a) is carried out in an organic solvent selected from the group consisting of non-polar aromatic solvents, ether solvents, chlorinated solvents, acetonitrile, dimethylformamide (DMF), methyl isobutyl ketone (MIBK), 2-butanone, acetone, isopropyl acetate (IPAc), ethyl acetate, and combinations thereof. In some cases, the organic solvent is selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, 1,2-dimethoxyethane, 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), cyclopentyl methyl ether (CPME), and combinations thereof. In some cases, the organic solvent is toluene, THF, DCM, or a combination thereof.

[0017] In various embodiments, step (a) is carried out at a temperature of from 20° C. to 100° C. In some cases, step (a) is carried out at a temperature of 60° C.

[0018] In various embodiments, removing the acetyl protecting group in step (b) comprises combining Compound C or a salt thereof with a deprotecting agent.

[0019] In various embodiments, the deprotecting agent comprises acetyl chloride, an enzyme, an acid, a base, a metal hydride, or a combination thereof.

[0020] In various embodiments, the deprotecting agent comprises acetyl chloride and an alcohol. In various embodiments, the alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, and combinations thereof. In some cases, the alcohol is methanol. In various embodiments, the deprotecting agent is magnesium methoxide. In various embodiments, the deprotecting agent is an enzyme selected from the group consisting of ester hydrolase, lipase, and combinations thereof. In various embodiments, the deprotecting agent is an acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, and combinations thereof. In various embodiments, the deprotecting agent is zirconium hydride.

[0021] In various embodiments, compound C and the deprotecting agent are present in a molar ratio of 1:0.2 to 1:2. In some cases, the molar ratio of compound C to the deprotecting agent is 1:0.5.

[0022] In various embodiments, step (b) is carried out at a temperature of from -15°C to 25°C. In some cases, step (b) is carried out at a temperature of 10°C.

[0023] In various embodiments, the oxidation in step (c) comprises combining compound D or a salt or solvate thereof and an oxidizing agent with an organic solvent and optionally water.

[0024] In various embodiments, the oxidizing agent is selected from the group consisting of oxalyl chloride / DMSO, bleach, SO3 / pyridine, iodobenzene diacetate, and any combination thereof. In some cases, the oxidizing agent is iodobenzene diacetate.

[0025] In various embodiments, compound D and the oxidizing agent are present in a molar ratio of 1:1.1 to 1:2. In some cases, the molar ratio of compound D to oxidizing agent is 1:1.1.

[0026] In various embodiments, the oxidation further comprises combining Compound D and the oxidation reagent with an oxidation catalyst. In various embodiments, the oxidation catalyst is selected from the group consisting of (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl (TEMPO), tetrapropylammonium perruthenate (TPAP) / N-methylmorpholine-N-oxide (NMO), Cu / 9-azabicyclo[3.3.1]nonane-N-oxyl (ABNO), Fe / ABNO, and combinations thereof. In some cases, the oxidation catalyst is TEMPO.

[0027] In various embodiments, compound D and the oxidation catalyst are present in a molar ratio of 1:0.01 to 1:1. In some cases, the molar ratio of compound D to oxidation catalyst is 1:0.04.

[0028] In various embodiments, the organic solvent (in step (c)) is selected from the group consisting of a non-polar aromatic solvent, an ether solvent, a chlorinated solvent, methyl isobutyl ketone (MIBK), 2-butanone, acetone, isopropyl acetate, ethyl acetate, and combinations thereof. In some cases, the organic solvent is selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, 1,2-dimethoxyethane, 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), cyclopentyl methyl ether (CPME), and combinations thereof. In some cases, the organic solvent is toluene.

[0029] In various embodiments, step (c) is carried out in the presence of water. In various embodiments, compound D and water are present in a molar ratio of 1:1 to 1:2. In some cases, the molar ratio of compound D to water is 1:1.1.

[0030] In various embodiments, step (c) is carried out at a temperature of from 5° C. to 45° C. In some cases, step (c) is carried out at a temperature of 20° C.

[0031] In various embodiments, protecting the aldehyde of compound E or a salt thereof in step (d) comprises combining compound E or a salt thereof and an aldehyde protecting group reagent with a solvent.

[0032] In various embodiments, the aldehyde protecting group reagent is selected from the group consisting of benzotriazole, bisulfite, cyanide salt, hydrogen cyanide, thiol or dithiol, alcohol or diol, hydrazine, ammonia, and combinations thereof. 1 teeth, [ka] In some cases, R 1 teeth, [ka] In some cases, R 1 teeth, [ka] is.

[0033] In various embodiments, compound E and the aldehyde protecting group reagent are present in a molar ratio of 1:1 to 1:1.5. In some cases, the molar ratio of compound E to the aldehyde protecting group reagent is 1:1.

[0034] In various embodiments, the solvent is selected from the group consisting of toluene, heptane, acetonitrile, water, methyl tert-butyl ether (MTBE), and combinations thereof. In various embodiments, the solvent in step (d) is selected from the group consisting of toluene / heptane, acetonitrile / water, and methyl tert-butyl ether (MTBE). In some cases, the solvent is toluene / heptane. In some cases, the toluene and heptane are present in the solvent in a volume ratio of 4:7.

[0035] In various embodiments, step (d) is carried out at a temperature between 20°C and 50°C.

[0036] In various embodiments, the method further comprises (e) crystallizing compound F.

[0037] In various embodiments, crystallizing comprises mixing Compound F with a crystallization solvent to form crystalline Compound F. In various embodiments, the crystallization solvent comprises heptane, toluene, methyl tert-butyl ether (MTBE), cyclopentyl methyl ether (CPME), methyl isobutyl ketone (MIBK), acetonitrile, isopropyl alcohol, isopropyl acetate, water, or a combination thereof.

[0038] In various embodiments, the method comprises using compound F to react with compound A1 [ka] or a salt or solvate thereof.

[0039] In various embodiments, the method comprises using compound F to react with compound A2 [ka] or a salt or solvate thereof.

[0040] Further provided herein is a compound of formula (I): [ka] (In the formula, R 1 teeth, [ka] or a protected aldehyde; R 2 OH or OPG 2 and OPG 2 is a secondary alcohol protecting group, with the proviso that R 2 If is OH, R 1 teeth, [ka] is) Compounds having the structure:

[0041] In various embodiments, R 1 teeth, [ka] In various embodiments, R 1 teeth, [ka] In various embodiments, R 1 is a protected aldehyde. In some cases, R 1 teeth, [ka] In some cases, R 1 teeth, [ka] In some cases, R 1 teeth, [ka] is.

[0042] In various embodiments, R 2is OH. In various embodiments, R 2 is OPG 2 In various embodiments, OPG 2 is selected from the group consisting of ether, acetal or ketal, acyl, sulfonyl, and silyl ether. In some cases, OPG 2 teeth, [ka] (methoxy), [ka] (tert-butyl ether), [ka] (methoxymethyl acetal, MOM), [ka] (2-methoxyethoxymethyl ether, MEM), [ka] (ethoxyethyl acetal, EE), [ka] (methoxypropyl acetal, MOP), [ka] (tetrahydropyranyl acetal, THP), [ka] (benzyloxymethyl acetal, BOM), [ka] (benzyl ether, Bn), [ka] (4-methoxybenzyl ether, PMB), [ka] (2-naphthyl methyl ether, Nap), [ka] (acetyl, Ac), [ka] Pivaloyl (Piv), [ka] (benzoyl, Bz), [ka] (4-bromobenzoyl, Br-Bz), [ka] (4-fluorobenzoyl), [ka] (4-chlorobenzoyl), [ka] (4-iodobenzoyl), [ka] (4-nitrobenzoyl), [ka] (4-phenylbenzoyl), [ka] (1-naphthoyl ester), [ka] (2-naphthoyl ester), [ka] (4-methoxybenzoyl), [ka] (isobutyryl), OSiEt3 (triethylsilyl ether, TES), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), OSiPh2 t Bu(tert-butyldiphenylsilyl ether TBDPS), OSO2Me(mesyl), [ka] (4-toluenesulfonyl, tosyl), [ka] (4-nitrobenzenesulfonyl, nosyl) and OSO2CF3 (triflyl). In some cases, OPG 2 is 4-bromobenzoyl.

[0043] In various embodiments, the compound is [ka] is selected from the group consisting of:

[0044] Further aspects and advantages will be apparent to those skilled in the art from a review of the following detailed description. The following description herein includes specific embodiments, with the understanding that the disclosure is illustrative and is not intended to limit the invention to the specific embodiments described herein. DETAILED DESCRIPTION OF THE INVENTION

[0045] Provided herein are methods for synthesizing Mcl-1 inhibitors and corresponding vinylcyclobutyl intermediates, particularly (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0] 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (Compound A1) or a salt or solvate thereof and (1S,3'R,6'R,7'R,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-7'-((9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylmethyl)-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-

[20] oxa

[13] thia[1,14]diazatetracyclo[14.7.2.0] 3,6 .0 19,24 ]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (Compound A2) or a salt or solvate thereof is provided. [ka]

[0046] U.S. Patent No. 9,562,061, the entirety of which is incorporated herein by reference, discloses compound A1 or a salt or solvate thereof as an Mcl-1 inhibitor and provides a method for preparing the same. The disclosure of salts and solvates of compound A1 from U.S. Patent No. 9,562,061 is incorporated by reference in its entirety. This patent also discloses a method for synthesizing the vinyl alcohol intermediate compound shown below, which is used in the synthesis of compound A1. [ka] Vinyl alcohol intermediates of the '061 patent

[0047] U.S. Patent No. 10,300,075, the entirety of which is incorporated herein by reference, discloses Compound A2 or a salt or solvate thereof as an Mcl-1 inhibitor and provides methods for its preparation. The disclosure of salts and solvates of Compound A2 from U.S. Patent No. 10,300,075 is incorporated by reference in its entirety.

[0048] The '061 patent describes a procedure for making a vinyl alcohol intermediate, shown below in Scheme 1, which is generally adapted from the disclosure in column 49 of the '061 patent. The '061 patent describes combining cyclobutanecarbaldehyde (intermediate II) with oxazepine (intermediate I) in a solvent at a temperature below room temperature, preferably 0° C. Sodium cyanoborohydride is added, and the mixture is added to a sodium hydroxide solution, thereby providing intermediate III. Advantageously, the methods described herein provide an improved synthetic route compared to General Procedure 1 of the '061 patent. The methods described herein can be carried out at ambient conditions (e.g., room temperature) and with milder reagents. Furthermore, the methods may provide a vinylcyclobutyl intermediate that allows for improved isolation, storage, and purity compared to the crystalline vinylcyclobutyl intermediate of the '061 patent. Scheme 1 - Basic Step 1 of the '061 Patent [ka]

[0049] The '061 patent further describes methods for synthesizing vinyl alcohol intermediate compounds using cyclobutyl intermediates, in which a vinyl group is added to the compound after the fragment containing the cyclobutyl intermediate has already been conjugated with a benzoxazepine moiety. For example, Scheme 2, shown below, is adapted from the disclosure in columns 66-71 of the '061 patent and represents a general method for synthesizing vinyl alcohols described in the '061 patent using cyclobutyl intermediates that do not contain a vinyl group. The '061 patent describes isolating each of the intermediate compounds before use in the next step of the synthesis. Advantageously, the use of vinylcyclobutyl intermediates and methods for making them described herein reduce steps in preparing vinyl alcohol intermediates and do not require isolation of the intermediates. Furthermore, the vinylcyclobutyl intermediates and methods for making them described herein enable convergent fragment assembly of compounds A1 and A2, provide superior purity profiles, provide highly crystalline intermediates for improved stability, and achieve higher yields overall, compared to the '061 patent. Scheme 2 - Synthesis of the vinyl alcohol intermediate of the '061 patent [ka]

[0050] Methods for synthesizing vinylcyclobutyl intermediates The present disclosure provides compound F: [ka] (In the formula, OPG 2 is a secondary alcohol protecting group, and R 1 is a protected aldehyde) or a salt thereof, comprising: (a) protecting a secondary alcohol of compound B or a salt thereof by reacting compound B or a salt thereof with an alcohol protecting group reagent to produce compound C: [ka] or a salt thereof; (b) Removal of the acetyl group of compound C to give compound D: [ka] or a salt thereof; and (c) oxidizing the primary alcohol of compound D or a salt thereof to obtain compound E: [ka] or a salt thereof; and (d) protecting the aldehyde of compound E or a salt thereof to form a protected aldehyde of compound F or a salt thereof; The present invention provides a method comprising:

[0051] A general reaction scheme for the methods described herein is provided below in Scheme 3. Scheme 3 - General method for the synthesis of cyclobutyl intermediates [ka]

[0052] Protection of secondary alcohols The disclosed method includes protecting the secondary alcohol of compound B or a salt thereof. In particular, compound B or a salt thereof is reacted with an alcohol protecting group reagent to form compound C or a salt thereof.

[0053] As provided herein, Compound B is [ka] In some embodiments, Compound B is a salt. Salts of Compound B or any other compound described herein can be prepared, for example, by reacting the free base form of the compound with a suitable organic or inorganic acid and optionally isolating the salt thus formed. Non-limiting examples of suitable salts for any one or more of the compounds described herein include hydrobromide, hydrochloride, sulfate, bisulfate, sulfonate, camphorsulfonate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulfonate, and amino acid salts.

[0054] Compound B is reacted with an alcohol protecting group reagent, thereby protecting the secondary alcohol of Compound B. Alcohol protecting groups are groups that mask hydroxyl functional groups and are well known in the art. The preparation of compounds can involve the protection and deprotection of various hydroxyl groups. The need for protection and deprotection and the selection of appropriate protecting groups and protecting group reagents can be easily determined by those skilled in the art. The chemical properties of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 4th Ed., Wiley & Sons, 2007, the entire contents of which are incorporated herein by reference. The adjustments of the alcohol protecting groups and the formation and cleavage methods described herein can be adjusted as necessary to take into account various substituents. Non-limiting examples of suitable alcohol protecting group reagents include acyl halides (e.g., acetyl chloride, pivaloyl chloride, 4-bromobenzoyl chloride, etc.), acyl anhydrides (e.g., acetic anhydride, maleic anhydride, etc.), silyl halides (e.g., trimethylsilyl chloride, chlorotriethylsilane, triisopropylsilyl chloride, etc.), and sulfonyl halides (e.g., methanesulfonyl chloride, etc.). The alcohol protecting group OPG described herein is 2Other alcohol protecting group reagents that can be used to provide: are also contemplated.

[0055] In some embodiments, the alcohol protecting group reagent is an acyl chloride or an acyl anhydride. For example, in some cases, the alcohol protecting group reagent is an acyl chloride such as 4-bromobenzoyl chloride. In some cases, the alcohol protecting group reagent is an acyl anhydride such as acetic anhydride.

[0056] Compound B and the alcohol protecting group reagent can be present in a molar ratio of 1:1 to 1:2, such as at least 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, or 1:1.6 and / or at most 1:2, 1:1.9, 1:1.8, 1:1.7, 1:1.6, 1:1.5, or 1:1.4, such as 1:1 to 1:1.8, 1:1 to 1:1.5, 1:1 to 1:1.4, or 1:1.2 to 1:1.4, etc. In some embodiments, the molar ratio of compound B to the alcohol protecting group reagent is 1:1.3.

[0057] In some embodiments, step (a) can include mixing compound B or a salt thereof, an alcohol protecting group reagent, and a nucleophilic catalyst. Non-limiting examples of nucleophilic catalysts include pyridine, dimethylaminopyridine (DMAP), and N-methylimidazole. In some embodiments, the nucleophilic catalyst includes pyridine, 4-dimethylaminopyridine, or a combination thereof. In some embodiments, the nucleophilic catalyst is pyridine. In some embodiments, the nucleophilic catalyst is DMAP.

[0058] When a nucleophilic catalyst is present, compound B and the nucleophilic catalyst can be present in a molar ratio of 1:1 to 1:5, e.g., at least 1:1, 1:1.5, 1:2, 1:2.5, 1:3, or 1:3.5 and / or at most 1:5, 1:4.5, 1:4, 1:3.5, or 1:3, e.g., 1:1 to 1:4, 1:2 to 1:5, 1:1.5 to 1:3.5, or 1:1 to 1:3, etc. In some embodiments, the molar ratio of compound B to the nucleophilic catalyst is 1:2.

[0059] The protection of the secondary alcohol can be carried out in an organic solvent. The organic solvent in step (a) can be selected from the group consisting of non-polar aromatic solvents, ether solvents, chlorinated solvents, acetonitrile, dimethylformamide (DMF), methyl isobutyl ketone (MIBK), 2-butanone, acetone, isopropyl acetate (IPAc), ethyl acetate, and combinations thereof. Non-limiting examples of non-polar aromatic solvents include toluene, benzene, xylene, chlorobenzene, fluorobenzene, naphthalene, and benzotrifluoride. Non-limiting examples of ether solvents include tetrahydrofuran (THF), tetrahydropyran, tetrahydrofurfuryl alcohol, diethyl ether, dibutyl ether, diisopropyl ether, methyl tert-butyl ether (MTBE), 1,2-dimethoxyethane, 1,4-dioxane, 2-methyl-THF, and cyclopentyl methyl ether. Non-limiting examples of chlorinated solvents include 1,2-dichloroethane, chloroform, carbon tetrachloride, and dichloromethane. Non-limiting examples of alcohol solvents include methanol, ethanol, propanol, 2-propanol, and tert-butanol.

[0060] In some embodiments, the organic solvent is selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, 1,2-dimethoxyethane, 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), cyclopentyl methyl ether (CPME), and combinations thereof. In some embodiments, the organic solvent is toluene, THF, DCM, or a combination thereof.

[0061] The organic solvent can be included in an amount of from 5 L / kg of Compound B to 25 L / kg of Compound B, e.g., at least about 5, 10, 15, or 20 L / kg of Compound B and / or up to about 25, 20, 25, or 10 L / kg of Compound B, e.g., 5 L / kg to 20 L / kg, 5 L / kg to 15 L / kg, or 5 L / kg to 10 L / kg, etc. In some embodiments, the solvent is present in an amount of 10 L / kg of Compound B.

[0062] Step (a) may be carried out at a temperature of 20°C to 100°C, e.g., at least 20, 25, 30, 35, 40, 45, 50, or 55°C and / or up to 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, or 50°C, such as 20°C to 80°C, 25°C to 75°C, 30°C to 70°C, 40°C to 70°C, 45°C to 65°C, or 50°C to 60°C. In some embodiments, step (a) is carried out at a temperature of 60°C.

[0063] Reaction of compound B with an alcohol protecting group reagent and optionally a nucleophilic catalyst forms compound C. As provided herein, compound C is [ka] (In the formula, OPG 2 is a secondary alcohol protecting group) or a salt thereof. The salt of Compound C can be similar to those described herein for Compound B.

[0064] As described above, alcohol protecting groups are groups that mask hydroxyl functional groups and are well known in the art. In some cases, the alcohol protecting group, OPG, 2 is selected from the group consisting of ethers, acetals or ketals, acyl and silyl ethers.

[0065] In some embodiments, OPG 2is an ether. Ether protecting groups contain either a substituted or unsubstituted alkyl moiety attached to the oxygen from the hydroxyl group that is protected (e.g., masked as an ether). Examples of suitable ethers include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, methoxymethyl acetal (MOM), 2-methoxyethoxymethyl ester (MEM), ethoxyethyl acetal (EE), and methoxypropyl ether (MOP). Other examples of contemplated ethers include, but are not limited to, benzyloxymethyl acetal (BOM), benzyl ether (Bn), 4-methoxybenzyl ether (PMB), and 2-naphthylmethyl ether (Nap).

[0066] In some embodiments, OPG 2 is an acetal or ketal. Acetals as protecting groups include: [ka] and can be used as an acetal (as an alternative to OR', where R' is, for example, an alkyl group) or a hemiacetal (as an alternative to OH), where RO comes from a protected hydroxyl group and PG' is the remainder of a (hemi)acetal protecting group. Ketals as protecting groups are [ka] where RO is derived from a protected hydroxyl group and can be used as a ketal (as an alternative to OR', where R' is, for example, an alkyl group) or a hemiketal (as an alternative to OH), and each PG' is derived from the remainder of a (hemi)ketal protecting group masking a hydroxyl group (i.e., R-OH) and can be substituted or unsubstituted. Examples of suitable acetals include, but are not limited to, tetrahydropyranyl acetal (THP).

[0067] In some embodiments, OPG 2is acyl. As used herein, the term "acyl" refers to an alcohol protecting group in which the oxygen atom of the alcohol is attached to the acyl group. [ka] where RO comes from the protected hydroxyl group and PG' comes from the remainder of the acyl protecting group. In some embodiments, the acyl protecting group is selected from the group consisting of acetyl, pivaloyl, benzoyl, 4-bromobenzoyl, 4-fluorobenzoyl, 4-chlorobenzoyl, 4-iodobenzoyl, 4-nitrobenzoyl, 4-phenylbenzoyl, 1-naphthoyl, 2-naphthoyl, 4-methoxybenzoyl, and isobutyryl.

[0068] In some embodiments, OPG 2 is a silyl ether. As used herein, the term "silyl ether" refers to an alcohol protecting group in which the oxygen atom of the alcohol is bonded to a silyl ether group. [ka] where RO is derived from a protected hydroxyl group and each PG' is derived from the remainder of a silyl ether protecting group. In some embodiments, the silyl ether protecting group is OSiEt3 (triethylsilyl ether, TES), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), and OSiPh2 t Bu (tert-butyldiphenylsilyl ether, TBDPS).

[0069] In some embodiments, OPG 2 is a sulfonyl protecting group. As used herein, the term "sulfonyl protecting group" refers to an alcohol protecting group in which the oxygen atom of the alcohol is bonded to a sulfonyl group. [ka] where RO comes from the protected hydroxyl group and PG' comes from the remainder of the sulfonyl protecting group. In some embodiments, the sulfonyl protecting group is selected from the group consisting of mesyl, tosyl, nosyl, and triflyl.

[0070] In some embodiments, OPG 2 teeth, [ka] (methoxy), [ka] (tert-butyl ether), [ka] (methoxymethyl acetal, MOM), [ka] (2-methoxyethoxymethyl ether, MEM), [ka] (ethoxyethyl acetal, EE), [ka] (methoxypropyl acetal, MOP), [ka] (tetrahydropyranyl acetal, THP), [ka] (benzyloxymethyl acetal, BOM), [ka] (benzyl ether, Bn), [ka] (4-methoxybenzyl ether, PMB), [ka] (2-naphthyl methyl ether, Nap), [ka] (acetyl, Ac), [ka] Pivaloyl (Piv), [ka] (benzoyl, Bz), [ka] (4-bromobenzoyl, Br-Bz), [ka] (4-fluorobenzoyl), [ka] (4-chlorobenzoyl), [ka] (4-iodobenzoyl), [ka] (4-nitrobenzoyl), [ka] (4-phenylbenzoyl), [ka] (1-naphthoyl ester), [ka] (2-naphthoyl ester), [ka] (4-methoxybenzoyl), [ka] (isobutyryl), OSO2Me (mesyl), [ka] (4-toluenesulfonyl, tosyl), [ka] (4-nitrobenzenesulfonyl, nosyl) and OSO2CF3 (triflyl). In some embodiments, OPG 2 is OSiEt3 (triethylsilyl ether, TES), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), OSiPh2 t Bu(tert-butyldiphenylsilyl ether TBDPS). In some embodiments, OPG 2 teeth, [ka] is.

[0071] Deprotection of primary alcohols The disclosed method includes removing the acetyl protecting group by combining Compound C or a salt thereof with a deprotecting agent, which is a secondary alcohol protecting group, OPG. 2The deprotecting agent can be selected to selectively deprotect the primary alcohol while preserving the protecting group. The selection of an appropriate protecting group can be readily determined by one of ordinary skill in the art. In some embodiments, the deprotecting agent includes acetyl chloride, an enzyme, an acid, a base, a metal hydride, or a combination thereof.

[0072] In some embodiments, the deprotecting agent includes acetyl chloride and an alcohol. As described herein, non-limiting examples of alcohol solvents include methanol, ethanol, propanol, 2-propanol, and tert-butanol. In some embodiments, the alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, and combinations thereof. In some embodiments, the alcohol is methanol.

[0073] Alcohol can be included in an amount of from 3 L / kg of Compound C to 15 L / kg of Compound C, e.g., at least about 3, 5, 7, 10, or 12 L / kg of Compound C and / or up to about 15, 12, 10, 7, or 5 L / kg of Compound C, e.g., 5 L / kg to 15 L / kg, 5 L / kg to 10 L / kg, or 5 L / kg to 7 L / kg of Compound C. In some embodiments, the solvent is present in an amount of 5.5 L / kg of Compound C.

[0074] In some embodiments, the deprotecting agent comprises a base. Non-limiting examples of bases include magnesium methoxide, magnesium ethoxide, and aluminum isopropoxide. In some embodiments, the deprotecting agent is magnesium methoxide. In some embodiments, the base is magnesium ethoxide. In some embodiments, the base is aluminum isopropoxide.

[0075] In some embodiments, the deprotecting agent comprises an enzyme. Non-limiting examples of suitable enzymes include ester hydrolases (e.g., NOVOZYM® 40086) and lipases (e.g., Amano Lipase PS). In some embodiments, the enzyme is selected from the group consisting of ester hydrolases, lipases, and combinations thereof. In some embodiments, the enzyme is an ester hydrolase. In some embodiments, the enzyme is a lipase.

[0076] In some embodiments, the deprotecting agent includes an acid or a metal triflate. Non-limiting examples of suitable acids include hydrochloric acid, sulfuric acid, phosphoric acid, trifluoroacetic acid (TFA), hydrobromic acid, and acetic acid. Non-limiting examples of suitable metal triflates include ytterbium triflate and dicyprosium triflate. In some embodiments, the deprotecting agent is an acid. In some embodiments, the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, and combinations thereof. In some embodiments, the acid is hydrochloric acid. In some embodiments, the acid is sulfuric acid. In some embodiments, the acid is phosphoric acid. In some embodiments, the deprotecting agent is a metal triflate. In some embodiments, the metal triflate is ytterbium triflate. In some embodiments, the metal triflate is dicyprosium triflate.

[0077] In some embodiments, the deprotecting agent includes a metal hydride or a borohydride. A non-limiting example of a metal hydride is zirconium hydride. A non-limiting example of a borohydride is lithium triethylborohydride. In some embodiments, the deprotecting agent is zirconium hydride. In some embodiments, the deprotecting agent is lithium triethylborohydride.

[0078] Compound C and the deprotecting agent can be present in a molar ratio of 1:0.2 to 1:2, e.g., at least about 1:0.2, 1:0.5, 1:0.7, 1:1, or 1:2 and / or at most 1:2, 1:1.7, 1:1.5, 1:1.2, 1:1, or 1:0.7, e.g., 1:0.2 to 1:1.5, 1:0.1 to 1:1, 1:0.2 to 1:0.7, or 1:0.3 to 1:0.6, etc. In some embodiments, the molar ratio of compound C to the deprotecting agent is 1:0.5.

[0079] Step (b) may be carried out at a temperature of -15°C to 25°C, for example, at least -15, -10, -5, -2, 0, 2, 5, or 10°C and / or up to 25, 20, 15, 10, 5, 2, or 0°C, for example, -15°C to 20°C, -10°C to 15°C, -5°C to 15°C, or 5°C to 15°C. In some embodiments, step (b) is carried out at a temperature of 10°C.

[0080] Removal of the acetyl protecting group of compound C gives compound D: [ka] (In the formula, OPG 2 is as described herein) or form a salt thereof. The salts of Compound D can be similar to those described herein for Compound B.

[0081] Oxidation of primary alcohols The methods described herein involve oxidizing a primary alcohol of compound D or a salt thereof to form an aldehyde of compound E. The oxidation involves combining compound D or a salt thereof and an oxidizing agent with an organic solvent and optionally water.

[0082] Suitable oxidizing agents are generally known in the art.Non-limiting examples of oxidizing agents include peracids such as m-chloroperbenzoic acid (mCPBA), hydrogen peroxide, tert-butyl hydroperoxide; perchlorates such as tetrabutylammonium perchlorate; chlorates such as sodium chlorate; chlorites such as sodium chlorite; hypochlorites such as bleach, periodates such as sodium periodate; high-valent iodine reagents such as iodosylbenzene and iodobenzene diacetate; manganese-containing reagents such as manganese dioxide and potassium permanganate; lead such as lead tetraacetate; chromium-containing reagents such as pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), Jones reagent; halogen compounds such as N-bromosuccinimide (NBS); oxygen; ozone; sulfur trioxide-pyridine complex; osmium tetroxide; selenium dioxide; 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). In some embodiments, the oxidizing agent is selected from the group consisting of oxalyl chloride / DMSO, bleach, SO3 / pyridine, iodobenzene diacetate, and any combination thereof, hi some embodiments, the oxidizing agent is iodobenzene diacetate.

[0083] Compound D and oxidizing agent can be present in a molar ratio of 1:1.1 to 1:2, e.g., at least 1:1.1, 1:1.2, 1:1.3, 1:1.4, or 1:1.5 and / or at most 1:2, 1:1.9, 1:1.8, 1:1.7, 1:1.6, or 1:1.5, e.g., 1:1.1 to 1:1.7, 1:1.1 to 1:1.5, 1:1.1 to 1:1.4, or 1:1.1 to 1:1.3, etc. In some embodiments, the molar ratio of compound D to oxidizing agent is 1:1.1.

[0084] The oxidation of the primary alcohol can further include combining Compound D and an oxidation reagent with an oxidation catalyst. Non-limiting examples of oxidation catalysts include (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl (TEMPO), tetrapropylammonium perruthenate (TPAP), 9-azabicyclo[3.3.1]nonane N-oxyl (ABNO), metal catalysts (e.g., copper, iron, etc.), 2-azaadamantane-N-oxyl, 1-methyl-2-azaadamantane-N-oxyl, 1,3-dimethyl-2-azaadamantane-N-oxyl, and 4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxoammonium tetrafluoroborate. In some embodiments, the oxidation catalyst is selected from the group consisting of (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl (TEMPO), tetrapropylammonium perruthenate (TPAP) / N-methylmorpholine-N-oxide (NMO), Cu / 9-azabicyclo[3.3.1]nonane-N-oxyl (ABNO), Fe / ABNO, and combinations thereof. In some embodiments, the oxidation catalyst is TEMPO.

[0085] When an oxidation catalyst is present, compound D and the oxidation catalyst can be present in a molar ratio of 1:0.01 to 1:1, e.g., at least 1:0.01, 1:0.04, 1:0.05, 1:0.1, 1:0.2, 1:0.3, or 1:0.5 and / or at most 1:1, 1:0.9, 1:0.7, 1:0.5, 1:0.2, or 1:0.1, e.g., 1:0.01 to 1:0.8, 1:0.01 to 1:0.5, 1:0.01 to 1:0.1, or 1:0.02 to 1:0.05, etc. In some embodiments, the molar ratio of compound D to oxidation catalyst is 1:0.04.

[0086] The oxidation of the primary alcohol can be carried out in an organic solvent. Suitable organic solvents include those generally described herein. In some embodiments, the organic solvent is selected from the group consisting of non-polar aromatic solvents, ether solvents, chlorinated solvents, methyl isobutyl ketone (MIBK), 2-butanone, acetone, isopropyl acetate, ethyl acetate, and combinations thereof. In some embodiments, the organic solvent is selected from the group consisting of toluene, benzene, xylene, tetrahydrofuran (THF), tetrahydropyran, diethyl ether, dibutyl ether, diisopropyl ether, dimethoxymethane, 1,2-dimethoxyethane, 1,4-dioxane, dichloromethane (DCM), carbon tetrachloride, chloroform, 1,2-dichloroethane, 2-methyltetrahydrofuran (2-MeTHF), methyl tert-butyl ether (MTBE), cyclopentyl methyl ether (CPME), and combinations thereof. In some embodiments, the organic solvent is toluene.

[0087] The organic solvent can be included in an amount of from 3 L / kg of compound D to 15 L / kg of compound D, e.g., at least about 3, 5, 7, 10, or 12 L / kg of compound D and / or up to about 15, 12, 10, 7, or 5 L / kg of compound D, e.g., 5 L / kg to 15 L / kg, 5 L / kg to 10 L / kg, or 5 L / kg to 7 L / kg. In some embodiments, the solvent is present in an amount of 6 L / kg of compound D.

[0088] The oxidation of the primary alcohol can be carried out in the presence of water. When present, compound D and water can be present in a molar ratio of 1:1 to 1:2, for example, at least 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, or 1:1.6 and / or at most 1:2, 1:1.9, 1:1.8, 1:1.7, 1:1.6, or 1:1.5, for example, 1:1 to 1:1.7, 1:1 to 1:5, 1:1.1 to 1:1.5, or 1:1 to 1:1.3. In some embodiments, the molar ratio of compound D to water is 1:1.1.

[0089] Step (c) may be carried out at a temperature of 5°C to 45°C, such as at least 5, 10, 15, 20, 25, or 30°C and / or at most 45, 40, 35, 30, 25, or 20°C, such as 5°C to 30°C, 10°C to 35°C, 15°C to 30°C, or 15°C to 25°C. In some embodiments, step (c) is carried out at a temperature of 20°C.

[0090] Oxidation of compound D or a salt thereof in step (c) gives compound E: [ka] (In the formula, OPG 2 is as described herein) or form a salt thereof. The salts of Compound E can be similar to those described herein for Compound B.

[0091] Protection of aldehydes The method of the disclosure includes protecting the aldehyde of compound E, or a salt thereof, to form a protected aldehyde of compound F, or a salt thereof. Protecting the aldehyde can include combining compound E, or a salt thereof, and an aldehyde-protecting group reagent with a solvent.

[0092] The term "protected aldehyde" or "aldehyde protecting group" refers to any protecting group used to mask an aldehyde functionality. Aldehyde protecting groups include acetals and hemiacetals. Acetals and hemiacetals are C 1~8 Alcohol or C 2~8The aldehyde protecting group R can be prepared from a diol. In some cases, the protected aldehyde is a 5- or 6-membered cyclic acetal formed from the condensation of an aldehyde with ethylene or propylene glycol. In some cases, the protected aldehyde is an imine or hydroxyimine. In some cases, the protected aldehyde comprises a bisulfite or benzotriazole. In some embodiments, the aldehyde protecting group reagent is selected from the group consisting of benzotriazole, bisulfite salts (e.g., sodium bisulfite, calcium bisulfite, lithium bisulfite, potassium bisulfite, etc.), cyanide salts (e.g., sodium cyanide, potassium cyanide, lithium cyanide), hydrogen cyanide, a thiol or dithiol, an alcohol or diol, hydrazine (or alkylhydrazine), ammonia, and combinations thereof. The aldehyde protecting group R described herein can be prepared from a 5- or 6-membered cyclic acetal formed from the condensation of an aldehyde with ethylene or propylene glycol. In some cases, the protected aldehyde is an imine or hydroxyimine. In some embodiments, the aldehyde protecting group R can be selected from the group consisting of benzotriazole, bisulfite salts (e.g., sodium bisulfite, calcium bisulfite, lithium bisulfite, potassium bisulfite, etc.), cyanide salts (e.g., sodium cyanide, potassium cyanide, lithium cyanide), hydrogen cyanide, a thiol or dithiol, an alcohol or diol, hydrazine (or alkylhydrazine), ammonia, and combinations thereof. 1 Other aldehyde protecting group reagents that provide:

[0093] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] (wherein the counter ion is, for example, a sodium ion) is.

[0094] Compound E and the aldehyde protecting group reagent can be present in a molar ratio of 1:1 to 1:1.5, for example, at least 1:1, 1:1.1, 1:1.2, or 1:1.3 and / or at most 1:1.5, 1:1.4, 1:1.3, or 1:1.2, for example, 1:1 to 1:1.4, 1:1 to 1:1.3, or 1:1.1 to 1:1.3, etc. In some embodiments, the molar ratio of compound E to the aldehyde protecting group reagent is 1:1.

[0095] The protection of the aldehyde can include a solvent, which can be selected from the organic solvents generally described herein. In some embodiments, the solvent is selected from the group consisting of toluene, heptane, acetonitrile, water, methyl tert-butyl ether (MTBE), and combinations thereof. In some embodiments, the solvent is selected from the group consisting of toluene / heptane, acetonitrile / water, and methyl tert-butyl ether (MTBE). In some embodiments, the solvent is toluene / heptane. The toluene and heptane can be present in a volume ratio of 1:10 to 10:1, e.g., 1:8 to 8:1, or 1:2 to 1:2. In some embodiments, the volume ratio of toluene to heptane is 4:7.

[0096] Step (d) may be carried out at a temperature of 20°C to 50°C, for example at least 20, 25, 30, 35 or 40°C and / or at most 50, 45, 40, 35 or 30°C, such as 20°C to 45°C, 25°C to 45°C, 30°C to 50°C, 35°C to 45°C or 30°C to 40°C.

[0097] Protection of the aldehyde of compound E or a salt thereof can be carried out to give compound F: [ka] (In the formula, R 1 and OPG 2 each of which is as described herein. The salts of Compound F can be similar to those described herein for Compound B.

[0098] Crystallization The method of the present disclosure may further include crystallizing Compound F or a salt thereof. Crystallization may include combining Compound F or a salt thereof with a crystallization solvent to form crystalline Compound F or a salt thereof. Suitable crystallization solvents are generally known in the art and may include, for example, water, methanol, ethanol, propanol, isopropanol, butanol, diethyl ether, isopropyl ether, methyl tert-butyl ether (MTBE), cyclopentyl methyl ether (CPME), methyl isobutyl ketone (MIBK), pentane, hexane, cyclohexane, heptane, acetone, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, ethyl acetate, isopropyl acetate, n-butyl acetate, dichloromethane, chloroform, 1,4-dioxane, and mixtures thereof.

[0099] In some embodiments, the crystallization solvent includes heptane, toluene, methyl tert-butyl ether (MTBE), cyclopentyl methyl ether (CPME), methyl isobutyl ketone (MIBK), acetonitrile, isopropyl alcohol, isopropyl acetate, water, or a combination thereof.

[0100] Compounds A1 and A2 can be synthesized using the methods for synthesizing compound F or a salt thereof described herein. Compound F can be used to synthesize compound A1 or a salt or solvate thereof, as shown in Scheme 4 below. Compound F can be used to synthesize compound A2 or a salt or solvate thereof, as shown in Scheme 5 below.

[0101] Scheme 4 - Conversion of Compound F to Compound A1 [ka] As shown in Scheme 4, compound F can be used to synthesize compound A1 and its salts and solvates. The synthesis of compound G and sulfonamide EE22 is disclosed in U.S. Pat. No. 9,562,061. Compounds F and G can be reacted to form compound H, a protected vinyl alcohol intermediate. Compounds EE22 and H can be reacted to form compound I. Cyclization and deprotection of compound I provides compound J, which can then be methylated to provide compound A1 as described in U.S. Pat. No. 9,562,061.

[0102] Scheme 5 - Conversion of Compound F to Compound A2 [ka] As shown in Scheme 5, compound F can be used to synthesize compound A2 and its salts and solvates. As described above with respect to Scheme 4, the synthesis of compound G and sulfonamide EE22 is disclosed in U.S. Pat. No. 9,562,061. Compounds G and F can be reacted to form compound H, a protected vinyl alcohol intermediate. Compounds EE22 and H can be reacted to form compound I, which can be cyclized to provide compound J. Compound J can then be oxidized to provide compound K, as disclosed in U.S. Pat. No. 10,300,075. Alternatively, compound I can be oxidized to provide the uncyclized version of compound J, which can then be cyclized to provide compound K. Compound K can then be epoxidized to compound L using the procedures disclosed in U.S. Pat. No. 10,300,075. Compound L can then be reacted with bicyclic compound M to provide compound N. Finally, methylation of compound N provides compound A2, as disclosed in U.S. Pat. No. 10,300,075.

[0103] In some embodiments, the method comprises using compound F to react with compound A1 [ka] or a salt or solvate thereof.

[0104] In some embodiments, the method comprises using compound F to react with compound A2 [ka] or a salt or solvate thereof. Cyclobutyl intermediate compound

[0105] The present disclosure provides a compound of formula (I): [ka] (In the formula, R 1 is CHO, [ka] or a protected aldehyde; R 2 OH or OPG 2 and OPG 2 is a secondary alcohol protecting group, with the proviso that R 2 If is OH, R 1 teeth, [ka] is) Also provided is a compound having the structure: or a salt thereof.

[0106] As provided herein, R 1 is CHO, [ka] or a protected aldehyde. In some embodiments, R 1 teeth, [ka] (i.e., an acetyl-protected primary alcohol). In some embodiments, R 1 teeth, [ka] (i.e., primary alcohol). In some embodiments, R 1 is CHO (i.e., aldehyde).

[0107] In some embodiments, R 1 is a protected aldehyde. In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] In some embodiments, R 1 teeth, [ka] (wherein the counter ion is, for example, a sodium ion) is.

[0108] As provided herein, R 2 OH or OPG 2 In some embodiments, R 2 is OH. R 2 If is OH, R 1 teeth, [ka] (i.e., the compound is [ka] (having the structure:

[0109] In some embodiments, R 2 is OPG 2 As used herein, OPG 2is a secondary alcohol protecting group. Suitable secondary alcohol protecting groups include those described herein. For example, in some embodiments, OPG 2 is selected from the group consisting of ether, acetal or ketal, acyl, silyl ether and sulfonyl.

[0110] In some embodiments, OPG 2 is an ether (e.g., methoxy, ethoxy, propoxy, butoxy, tert-butoxy, methoxymethyl acetal (MOM), 2-methoxyethoxymethyl ester (MEM), ethoxyethyl acetal (EE), and methoxypropyl ether (MOP), benzyloxymethyl acetal (BOM), benzyl ether (Bn), 4-methoxybenzyl ether (PMB), and 2-naphthylmethyl ether (Nap)). In some embodiments, OPG 2 is an acetal or ketal (e.g., tetrahydropyranyl acetal (THP)). In some embodiments, OPG 2 is acyl (e.g., acetyl, pivaloyl, benzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, 4-phenylbenzoyl, 1-naphthoyl, 2-naphthoyl, 4-methoxybenzoyl, isobutyryl). 2 is a silyl ether (e.g., OSiEt3 (triethylsilyl ether, TES)), OSi( i Pr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), OSiPh2 t Bu(tert-butyldiphenylsilyl ether TBDPS)). In some embodiments, OPG 2 is sulfonyl (e.g., mesyl, tosyl, nosyl, triflyl).

[0111] In some embodiments, OPG 2 teeth, [ka] (methoxy), [ka] (tert-butyl ether), [ka] (methoxymethyl acetal, MOM), [ka] (2-methoxyethoxymethyl ether, MEM), [ka] (ethoxyethyl acetal, EE), [ka] (methoxypropyl acetal, MOP), [ka] (tetrahydropyranyl acetal, THP), [ka] (benzyloxymethyl acetal, BOM), [ka] (benzyl ether, Bn), [ka] (4-methoxybenzyl ether, PMB), [ka] (2-naphthyl methyl ether, Nap), [ka] (acetyl, Ac), [ka] Pivaloyl (Piv), [ka] (benzoyl, Bz), [ka] (4-bromobenzoyl, Br-Bz), [ka] (4-fluorobenzoyl), [ka] (4-chlorobenzoyl), [ka] (4-iodobenzoyl), [ka] (4-nitrobenzoyl), [ka] (4-phenylbenzoyl), [ka] (1-naphthoyl ester), [ka] (2-naphthoyl ester), [ka] (4-methoxybenzoyl), [ka] (isobutyryl), OSiEt3 (triethylsilyl ether, TES), OSi( iPr)3 (triisopropylsilyl ether, TIPS), OSiMe3 (trimethylsilyl ether, TMS), OSiMe2tBu (tert-butyldimethylsilyl ether, TBS), OSiPh2 t Bu(tert-butyldiphenylsilyl ether TBDPS), OSO2Me(mesyl), [ka] (4-toluenesulfonyl, tosyl), [ka] (4-nitrobenzenesulfonyl, nosyl) and OSO2CF3 (triflyl). In some embodiments, OPG 2 is 4-bromobenzoyl.

[0112] In some embodiments, the compound is [ka] is selected from the group consisting of:

[0113] While this disclosure is to be read in conjunction with its detailed description, it is to be understood that the foregoing description and the following examples are exemplary and do not limit the scope of the disclosure, which is intended to be defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. [Example]

[0114] The following examples are provided for illustrative purposes and are not intended to limit the scope of the present invention.

[0115] Example 1: Protection of secondary alcohols (S)-1-((1R,2R)-2-(acetoxymethyl)cyclobutyl)allyl 4-bromobenzoate was prepared according to the following reaction scheme. [ka]

[0116] A 3100 L glass-lined reactor was flushed with nitrogen and charged with compound B (363.5 kg, 25.3 w / w% in toluene, 1.00 equiv.), pyridine (81 L, 2.0 equiv.), and toluene (287 L, 3.1 L / kg). The mixture was stirred at 20°C until homogeneous. Subsequently, a solution of 4-bromobenzoyl chloride (143 kg, 1.30 equiv.) in toluene (380 L, 4.1 L / kg) was charged to the reaction mixture. The reaction mixture was heated to 60°C and held for 4 hours or until the reaction was judged complete by HPLC analysis. The reaction was cooled to 5°C and quenched with 1 M HCl (367 L, 4 L / kg). The reaction mixture was filtered through a 20 μm filter into a clean 14300 L glass-lined reactor that had previously been rinsed with toluene (184 L, 2 L / kg). The biphasic mixture was warmed to 20°C and the phases were separated. The toluene solution was washed sequentially with sodium bicarbonate solution (5% w / w, 368 L, 4 L / kg) and water (368 L, 4 L / kg). The toluene solution was then concentrated to a volume of approximately 184 L, maintaining the internal temperature at <40°C. n-Heptane (460 L, 5 L / kg) was charged to the reactor, and the resulting solution was cooled to 5°C. After stirring at 5°C for 1 hour, the reaction mixture was filtered through a 0.5 μm sparkler filter into a clean 6700 L glass-lined reactor that had previously been rinsed with n-heptane (110 L, 1.2 L / kg). The mixture was concentrated to a volume of approximately 262 L, maintaining the internal temperature at <40°C. The resulting solution of compound C was cooled to 20°C and used directly in the next step.

[0117] 1H NMR(600MHz,DMSO)δ 7.92(d,J=8.5Hz,2H),7.76(d,J=8.5Hz,2H),5.85(ddd,J=17.1,10.6,6.1Hz,1H),5.42(ddt, J=8.0,6.1,1.4Hz,1H),5.27(dt,J=17.1,1.4Hz,1H),5.20(dt,J=10.6,1.4Hz,1H),3.97(dd, J=11.4,6.0Hz,1H),3.95(dd,J=11.4,6.0Hz,1H),2.55-2.49(m,1H),2.47(qui,J=8.0Hz,1H) ,1.94-1.87(m,2H),1.87(s,3H),1.72(dq,J=10.7,9.1Hz,1H),1.64(dq,J=11.3,9.1Hz,1H). 13 C NMR(151MHz,DMSO)δ 170.3,164.3,134.5,131.9,131.1,128.9,127.5,117.1,77.6,66.6,40.5,36.4,20.5,20.5,19.9.LRMS(ESI):C 17 H 19 Calculated for BrO4+H: 367, Found: 367.

[0118] Example 2: Deprotection of primary alcohols (S)-1-((1R,2R)-2-(hydroxymethyl)cyclobutyl)allyl 4-bromobenzoate was prepared according to the following reaction scheme. [ka]

[0119] A 6700 L glass-lined reactor containing approximately 262 L of compound C solution was charged with methanol (938 L, 5.5 L / kg) and cooled to 1 °C. Acetyl chloride (16 L, 0.5 equiv.) was charged at a rate to maintain an internal temperature of <5 °C. The reaction mixture was stirred at 10 °C for 10 hours or until judged complete by HPLC analysis. The reaction mixture was diluted with toluene (1750 L, 10 L / kg) and then quenched with sodium bicarbonate solution (5 w / w%, 852 L, 5 L / kg) and sodium chloride solution (5 w / w%, 170 L, 1 L / kg). The biphasic mixture was warmed to 20 °C and the phases were separated. The toluene layer was washed with water (852 L, 5 L / kg). The mixture was concentrated to a volume of approximately 186 L while maintaining an internal temperature of <40 °C. HPLC assay gave compound C (317.5 kg, 48.8 w / w% in toluene), which was used directly in the next step.

[0120] 1 H NMR(600MHz,DMSO)δ 7.91(d,J=8.6Hz,2H),7.76(d,J=8.6Hz,2H),5.86(ddd,J=17.2,10.7,5.7Hz,1H),5.40( ddt,J=8.0,5.7,1.4Hz,1H),5.26(dt,J=17.2,1.4Hz,1H),5.19(dt,J=10.7,1.4Hz,1H), 4.43(t,J=5.7Hz,1H),3.36(dt,J=10.3,5.7Hz,1H),3.31(dt,J=10.3,5.7Hz,1H),2.42( qui,J=8.0Hz,1H),2.30(quid,J=8.0,4.2Hz,1H),1.90-1.77(m,2H),1.73-1.60(m,2H). 13 C NMR(151MHz,DMSO)δ 164.4,134.8,131.9,131.1,129.1,127.4,116.9,78.1,64.0,40.0,39.6,20.4,19.9.LRMS(ESI):C 15 H 17 Calculated for BrO3 + H: 325, Found: 325.

[0121] Example 3: Oxidation of primary alcohols (S)-1-((1R,2R)-2-formylcyclobutyl)allyl 4-bromobenzoate was prepared according to the following reaction scheme. [ka]

[0122] A 3600 L stainless steel reactor was flushed with nitrogen and charged with compound D (317.5 kg, 48.8 w / w% in toluene, 1.00 equiv.) and toluene (930 L, 6 L / kg). The mixture was stirred at 20°C until homogeneous. Water (9.5 L, 1.10 equiv.) and (diacetoxyiodo)benzene (169 kg, 1.10 equiv.) were charged to the reactor. The heterogeneous mixture was cooled to 15°C. A solution of TEMPO (2.9 kg, 0.04 equiv.) in toluene (155 L, 1 L / kg) was charged at a rate to maintain an internal temperature of <20°C. The reaction mixture was warmed to 20°C and held there for 12 hours or until the reaction was judged complete by HPLC analysis. The reaction was quenched with sodium thiosulfate solution (5 w / w%, 775 L, 5.0 L / kg) and the phases were separated. The toluene layer was washed sequentially with sodium carbonate solution (5 w / w%, 775 L, 5.0 L / kg) and two portions of water (775 L, 5.0 L / kg). The mixture was concentrated to a volume of approximately 465 L, maintaining the internal temperature at <40° C. The resulting solution of compound E was cooled to 20° C. and used directly in the next step.

[0123] 1 H NMR(600MHz,DMSO)δ 9.61(d,1.9Hz,1H),7.90(d,8.2Hz,2H),7.75(d,8.2Hz,2H),5.85(dddd,17.3,10.6,6.0,0.6Hz,1H),5.44(ddt,7.4,6.0,1.4Hz,1H),5.30(dtd,17 .3,1.4,0.6Hz,1H),5.22(dq,10.6,1.4,0.6Hz,1H),3.23-3.15(m,1H),2. 93-2.85(m,1H),2.11-2.02(m,1H),2.00-1.94(m,1H),1.89-1.82(m,2H); 13C NMR(151MHz,DMSO)δ 202.2,164.3,134.1,131.9,131.1,128.8,127.5,117.6,77.2,47.3,38.4,19.9,18.0.LRMS(ESI):C 15 H 15 Calculated for BrO3 + H: 323, Found: 323.

[0124] Example 4: Protection of Aldehydes (1S)-1-((1R,2R)-2-((1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)cyclobutyl)allyl 4-bromobenzoate was prepared according to the following reaction scheme. [ka]

[0125] A 3600 L stainless steel reactor containing approximately 465 L of compound E solution was charged with benzotriazole (56.5 kg, 1.00 equiv.). The mixture was stirred at 20°C until homogeneous. The resulting solution was filtered through a 0.5 μm polyester filter into a clean 3600 L stainless steel reactor previously rinsed with toluene (155 L, 1 L / kg). The reaction mixture was heated to 50°C. n-Heptane (310 L, 2 L / kg) was then charged at a rate to maintain an internal temperature >45°C. Ground compound F seeds (3.2 kg, 2.0 w / w%) were charged to the reactor, and the suspension was held at 50°C for 1 hour. n-Heptane (622.5 L, 4 L / kg) was added to the reactor over 10 hours to maintain an internal temperature of 50°C, after which a cooling ramp to 20°C over 4 hours was initiated. n-Heptane (310 L, 2 L / kg) was added to the reactor over 2 hours to maintain an internal temperature of 20°C, after which a 4-hour hold was initiated. The heterogeneous mixture was transferred to a 1260 L Hastelloy agitated filter drier for deliquification. The filter cake was washed sequentially with a 1:1 mixture of toluene:n-heptane (310 L, 2 L / kg) and n-heptane (310 L, 2 L / kg). The cake was dried under vacuum while maintaining an internal temperature of <50°C. Compound F (170 kg) was isolated in 80% molar yield by HPLC assay.

[0126] 1H NMR(600MHz,DMSO)δ 8.01(dt,J=8.3,1.0Hz,1H),7.92(d,J=8.6Hz,2H),7.88(dt,J=8.3,1.0Hz,1H),7.73(d,J=8.6Hz,2H),7.53(ddd,J=8.3,6.9,1.0Hz, 1H),7.39(ddd,J=8.3,6.9,1.0Hz,1H),7.22(d,J=5.8Hz,1H),6.29(dd,J=8.7,5.8Hz,1H),5.96(ddd,J=17.3,10.6,6.4Hz,1H),5.57 (tt,J=6.4,1.2Hz,1H),5.33(dt,J=17.3,1.4Hz,1H),5.25(dt,J=10.6,1.4Hz,1H),3.20(qui,J=8.7Hz,1H),2.78(qui,J=8.7Hz,1H) ,1.93(dtd,J=11.6,8.7,3.8Hz,1H),1.75(dq,J=11.6,8.7Hz,1H),1.62(ddd,J=11.9,8.7,3.8Hz,1H),1.56(dt,J=11.9,8.7Hz,1H); 13 C NMR(150MHz,DMSO)δ 164.6,145.5,134.3,131.7,131.7,131.2,129.4,127.1,127.0,123.9,119.1,117.7,111.6,85.9,77.4,41.7,40.6,19.4,19.0.LRMS(ESI):C 21 H 20 Calculated value of BrN3O3+Hについての: 442, measured value: 442.

Claims

1. Formula (I): 【Chemistry 1】 (In the formula, R １ teeth, 【Chemistry 2】 is selected from the group consisting of R ２ teeth, 【Transformation 3】 (4-bromobenzoyl, Br-Bz), 【Chemistry 4】 (4-fluorobenzoyl), 【Transformation 5】 (4-chlorobenzoyl), and 【Transformation 6】 (4-iodobenzoyl) is selected from the group consisting of A compound having the structure:

2. R １ teeth, 【Transformation 7】 2. The compound of claim 1, wherein:

3. R １ teeth, 【Transformation 8】 2. The compound of claim 1, wherein:

4. R １ teeth, 【Chemistry 9】 2. The compound of claim 1, wherein:

5. R １ teeth, 【Chemistry 10】 2. The compound of claim 1, wherein:

6. R ２ teeth, 【Chemistry 11】 (4-bromobenzoyl, Br-Bz), 【Chemistry 12】 (4-fluorobenzoyl), and 【Chemistry 13】 (4-chlorobenzoyl) 2. The compound of claim 1 selected from the group consisting of:

7. R 2 is 【Chemistry 14】 (4-Bromobenzoyl, Br-Bz) 2. The compound of claim 1, wherein: 【Request Item 8】 【Chemistry 15】 2. The compound of claim 1 selected from the group consisting of:

Images